CureVac N.V (CVAC) News

CureVac N.V (CVAC): $6.97

0.30 (+4.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CVAC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 379

in industry

Filter CVAC News Items

CVAC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CVAC News Highlights

  • CVAC's 30 day story count now stands at 2.
  • Over the past 5 days, the trend for CVAC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest CVAC News From Around the Web

Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

CureVac Announces Voting Results of Extraordinary General Meeting

/ CureVac N.V.

Yahoo | March 28, 2023

As CureVac N.V.'s market cap (NASDAQ:CVAC) drops to US$1.4b, insiders might be questioning their decision to buy earlier this year

The recent 7.1% drop in CureVac N.V.'s ( NASDAQ:CVAC ) stock could come as a blow to insiders who purchased €97m worth...

Yahoo | March 23, 2023

The past year for CureVac (NASDAQ:CVAC) investors has not been profitable

While it may not be enough for some shareholders, we think it is good to see the CureVac N.V. ( NASDAQ:CVAC ) share...

Yahoo | February 23, 2023

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

/ CureVac N.V.

Yahoo | February 10, 2023

CureVac Announces Proposed Public Offering of Common Shares

CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of its common shares in an underwritten public offering.

Yahoo | February 7, 2023

CureVac Welcomes Myriam Mendila as New Chief Development Officer

/ CureVac N.V.

Yahoo | February 1, 2023

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)

/ CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its inclusion in the second annual "Innovation Momentum: Global Top 100" report by LexisNexis®. Top 100 recognizes companies advancing innovative solutions to address today's challenges and laying the intellectual property foundations for further breakthroughs.

Yahoo | January 31, 2023

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs

CureVac N.V. (NASDAQ: CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK plc (NYSE: GSK). The newly reported data focus on older adult age groups. COVID-19 Program Newly reported immunogenicity data from CV0501 in older adults (age ≥65) are based on the fully recruited dose groups of 12, 25 and 50µg, consisting of 10 subjects per dose. On day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to

Yahoo | January 30, 2023

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced positive extended preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu conducted in collaboration with GSK. The newly reported data focus on older adult age groups in both indications. Detailed data can be reviewed in the associated presentation.

Yahoo | January 30, 2023

The 3 Best Biotech Stocks Under $1 to Buy for January

Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.

Dana Blankenhorn on InvestorPlace | January 26, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6973 seconds.